Although Parkinson's disease (PD) is estimated to be the second most common neurodegenerative disorder, very little is known about its underlying cause. That could be about to change as scientists continue to drill down into the molecular machinery implicated in the disease. Recent scientific discoveries are beginning to open up the potential for both the development of innovative approaches to early diagnosis and treatment.
Read More
Three pharmas have teamed up to create the Investigator Databank to benefit clinical trial investigators by reducing administrative redundancy and to make it easier for the companies to find investigators for their clinical trials. Read More
On the capital markets, biotechnology has done remarkably well despite the continuing turbulent economic landscape, particularly in Europe. With about 25 trading days left, the sector is poised to close out 2012 well ahead of where it started. Read More
